Literature DB >> 11726221

Cellular immune response against tropomyosin isoform 5 in ulcerative colitis.

M Taniguchi1, X Geng, K D Glazier, A Dasgupta, J J Lin, K M Das.   

Abstract

We have reported an autoantibody response in ulcerative colitis (UC) against human tropomyosin isoform 5 (hTM5), the predominant colonic epithelial cell hTM isoform. In this report, we determined the number of IFN-gamma-secreting cells (spot-forming cells, SFC) against hTM5 by an enzyme-linked immunospot (ELISPOT) assay. Another cytoskeletal protein, caldesmon, CaD40, was used as a control antigen. Peripheral blood mononuclear cells were separated by a Ficoll density gradient from 28 patients with UC, 13 patients with Crohn's disease (CD), and 9 healthy subjects (HS). The mean (+/-SEM) SFC values against hTM5 in UC, CD, and HS were 48.8 +/- 8.1, 18.6 +/- 4.6, and 20.8 +/- 8.6, respectively. The value in UC was significantly higher than those in CD (P < 0.005) and HS (P < 0.025). SFC values in CD did not differ from those in HS. None of the 50 samples (except 1 UC) reacted to the CaD40 antigen. This study demonstrates, for the first time, a defined colon epithelial cell antigen, hTM5, that is capable of inducing a significant T cell response in UC but not in CD. (c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726221     DOI: 10.1006/clim.2001.5133

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia.

Authors:  Koushik K Das; Manisha Bajpai; Yingxin Kong; Jianying Liu; Xin Geng; Kiron M Das
Journal:  Mol Pharmacol       Date:  2009-04-15       Impact factor: 4.436

2.  Accumulation of tropomyosin isoform 5 at the infection sites of host cells during Cryptosporidium invasion.

Authors:  Steven P O'Hara; Jim Jung-Ching Lin
Journal:  Parasitol Res       Date:  2006-02-15       Impact factor: 2.289

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.